Need for new technologies for detection of adventitious agents in vaccines and other biological products

PDA Journal of Pharmaceutical Science and Technology

Volumn 68, Issue 6, 2014, Pages 556-562

  Mallet, Laurent ^a   Gisonni Lex, Lucy ^b  

^a SANOFI PASTEUR   (France)

^b Sanofi Pasteur   (Canada)

Author keywords

Adventitious agents; Biological products; Cell substrates; Next Generation sequencing; Product safety; Regulatory harmonization; Viral vaccines; Virus detection assays

Indexed keywords

BIOLOGICAL PRODUCT; BIOMATERIAL; INACTIVATED VACCINE; INTERFERON; LIVE VACCINE; MONOCLONAL ANTIBODY; RECOMBINANT DNA; ROTAVIRUS VACCINE; VIRUS VACCINE; VACCINE; VIRUS DNA;

BIOINFORMATICS; BLOOD; CIRCOVIRUS; CONFERENCE PAPER; CYTOPATHOGENIC EFFECT; HIGH THROUGHPUT SEQUENCING; HUMAN; NONHUMAN; PRODUCT SAFETY; RISK ASSESSMENT; VESICULAR STOMATITIS VIRUS; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS INFECTIVITY; DRUG CONTAMINATION; GENETICS; ISOLATION AND PURIFICATION; PATIENT SAFETY; PHARMACEUTICS; PREVENTION AND CONTROL; PROCEDURES; STANDARDS; VIROLOGY; VIRUS;

BIOPHARMACEUTICS; CONSUMER PRODUCT SAFETY; DNA, VIRAL; DRUG CONTAMINATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PATIENT SAFETY; TECHNOLOGY, PHARMACEUTICAL; VACCINES; VIROLOGY; VIRUSES;

EID: 84915754759     PISSN: 10797440     EISSN: 19482124     Source Type: Journal    
DOI: 10.5731/pdajpst.2014.01012     Document Type: Conference Paper

References (15)

1. World Health Organization (WHO). Recommendations for the evaluation of animal cell cultures as cell substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Sixty-First Report; World Health Organization, Annex 3, WHO Technical Report Series No. 978; Geneva, Switzerland, 2013.
2. International Conference on Harmonisation. ICH Topics Q5A(R1) - Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 23 Sept 1999.
3. Code of Federal Regulations, Title 9, Animal and Animal Products (current year): Part 113.53, Requirements for ingredients of animal origin used for production of biologics; Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington, DC; January 1, 2011.
4. Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; FDA: Rockville, MD, February 2010.
5. CBER. Points to consider in the characterization of cell lines used to produce biologicals. FDA: Rockville, MD, July 1993.
6. CBER. Points to consider in the manufacture and testing of monoclonal antibody products for human use. U.S. FDA: Rockville, MD, February 1997.
7. Chapter 5.2.3, Cell Substrates for the Production of Vaccines for Human Use. European Pharmacopoeia, 8th ed., 2013.
8. Chapter 2.6.16, Tests for Extraneous Agents in Viral Vaccines for Human Use. European Pharmacopoeia, 8th ed., 2013.
9. ICH Topics Q2R1 - Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonisation, November 2005.
10. Sheets, R. L. Opinion on adventitious agents testing for vaccines: Why do we worry so much about adventitious agents in vaccines? Vaccine 2013, 31 (26), 2791-2795.
11. Gombold, J.; Karakasidis, S.; Niksa, P.; Podczasy, J.; Neumann, K.; Richardson, J.; Sane, N.; Johnson-Leva, R.; Randolph, V.; Sadoff, J.; Minor, P.; Schmidt, A.; Duncan, P.; Sheets, R. L. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products. Vaccine 2014, 32 (24) 2916-2926.
12. Victoria, J. G.; Wang, C.; Jones, M. S.; Jaing, C.; McLoughlin, K.; Gardner, S.; Delwart, E. L. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033-6040.
13. Onions, D.; Kolman, J. Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38 (3), 377-380.
14. Onions, D.; Côté, C.; Love, B.; Toms, B.; Koduri, S.; Armstrong, A.; Chang, A.; Kolman, J. Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome. Vaccine 2011, 29 (41), 7117-7121.
15. Cheval, J.; Sauvage, V.; Frangeul, L.; Dacheux, L.; Guigon, G.; Dumey, N.; Pariente, K.; Rousseaux, C.; Dorange, F.; Berthet, N.; Brisse, S.; Moszer, I.; Bourhy, H.; Manuguerra, C. J.; Lecuit, M.; Burguiere, A.; Caro, V.; Eloit, M. Evaluation of high-throughput sequencing for identifying known and unknown viruses in biological samples. J. Clin. Microbiol. 2011, 49 (9), 3268-3275.